Cholesterol esterification inhibition affects low density lipoprotein (LDL) receptors. Reversible inhibitors cause LDL receptor downregulation by accumulating intracellular cholesterol, while irreversible inhibitors do not.
Area of Science:
Cell Biology
Biochemistry
Molecular Biology
Background:
Fibroblasts normally regulate low density lipoprotein (LDL) receptors in response to cholesterol levels.
Cholesterol esterification is a continuous process in cells, even when cholesterol-deprived.
Acyl-CoA: cholesterol acyl-transferase (ACAT) is a key enzyme in cholesterol esterification.
Purpose of the Study:
To investigate the role of cholesterol esterification in regulating LDL receptor expression.
To determine if inhibition of cholesterol esterification affects LDL receptor binding and metabolism.
To differentiate the effects of reversible versus irreversible ACAT inhibitors on LDL receptors.
Main Methods:
Utilized cholesterol-deprived fibroblasts to induce LDL receptors.
Administered structurally unrelated ACAT inhibitors: progesterone, trimethylcyclohexanyl mandelate, and 58035.
Measured basal cholesterol esterification rates.
Assessed specific binding and metabolism of LDL after inhibitor exposure.
Examined the time-dependent effects of inhibitors on LDL receptor function.
Main Results:
Progesterone, trimethylcyclohexanyl mandelate, and 58035 all inhibited basal cholesterol esterification within 1 hour.
Progesterone and trimethylcyclohexanyl mandelate (reversible inhibitors) caused decreased LDL binding and metabolism after 17 hours.
This downregulation was time-dependent and linked to reversible inhibition of esterification.
The irreversible inhibitor 58035 did not affect LDL receptor number.